German Corrales
Concepts (71)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Receptors, Opioid, mu | 2 | 2021 | 51 | 0.350 |
Why?
| Hyperthermia, Induced | 2 | 2021 | 120 | 0.340 |
Why?
| Head and Neck Neoplasms | 2 | 2021 | 288 | 0.280 |
Why?
| Ganglia, Spinal | 2 | 2024 | 53 | 0.270 |
Why?
| Neoplasms | 3 | 2022 | 1325 | 0.260 |
Why?
| Pain, Postoperative | 3 | 2022 | 169 | 0.230 |
Why?
| Radiculopathy | 1 | 2024 | 15 | 0.230 |
Why?
| Action Potentials | 1 | 2024 | 120 | 0.220 |
Why?
| Erythrocyte Transfusion | 1 | 2021 | 52 | 0.180 |
Why?
| Analgesia, Epidural | 1 | 2021 | 28 | 0.180 |
Why?
| Naltrexone | 1 | 2021 | 64 | 0.170 |
Why?
| Peritoneal Neoplasms | 1 | 2021 | 65 | 0.170 |
Why?
| Antineoplastic Agents, Phytogenic | 1 | 2021 | 71 | 0.170 |
Why?
| Cell Proliferation | 2 | 2021 | 1023 | 0.170 |
Why?
| Peripheral Nervous System Diseases | 1 | 2021 | 59 | 0.170 |
Why?
| Narcotic Antagonists | 1 | 2021 | 139 | 0.170 |
Why?
| Acute Pain | 1 | 2019 | 11 | 0.160 |
Why?
| Opioid-Related Disorders | 1 | 2024 | 400 | 0.160 |
Why?
| Pain Management | 1 | 2019 | 178 | 0.140 |
Why?
| Telemedicine | 1 | 2024 | 494 | 0.140 |
Why?
| Antineoplastic Agents | 1 | 2021 | 1222 | 0.100 |
Why?
| Humans | 12 | 2024 | 52483 | 0.090 |
Why?
| Mice, Nude | 2 | 2021 | 265 | 0.090 |
Why?
| Cell Line, Tumor | 2 | 2021 | 1470 | 0.070 |
Why?
| Mice, Inbred C57BL | 2 | 2021 | 1884 | 0.060 |
Why?
| Nociceptors | 1 | 2024 | 9 | 0.060 |
Why?
| Sensory Receptor Cells | 1 | 2024 | 11 | 0.060 |
Why?
| Sulfones | 1 | 2024 | 25 | 0.060 |
Why?
| Neuralgia | 1 | 2024 | 43 | 0.050 |
Why?
| Male | 4 | 2024 | 26761 | 0.050 |
Why?
| Translations | 1 | 2022 | 7 | 0.050 |
Why?
| Adult | 3 | 2024 | 14161 | 0.050 |
Why?
| Nausea | 1 | 2022 | 46 | 0.050 |
Why?
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2021 | 10 | 0.050 |
Why?
| Animals | 3 | 2021 | 13505 | 0.050 |
Why?
| Quaternary Ammonium Compounds | 1 | 2021 | 30 | 0.050 |
Why?
| Abdominal Muscles | 1 | 2021 | 14 | 0.040 |
Why?
| Multicenter Studies as Topic | 1 | 2021 | 105 | 0.040 |
Why?
| Tumor Burden | 1 | 2021 | 136 | 0.040 |
Why?
| Cells, Cultured | 1 | 2024 | 1567 | 0.040 |
Why?
| Epithelial-Mesenchymal Transition | 1 | 2021 | 57 | 0.040 |
Why?
| Perioperative Care | 1 | 2021 | 43 | 0.040 |
Why?
| Xenograft Model Antitumor Assays | 1 | 2021 | 220 | 0.040 |
Why?
| Mice | 2 | 2021 | 5949 | 0.040 |
Why?
| Feasibility Studies | 1 | 2022 | 406 | 0.040 |
Why?
| Retrospective Studies | 2 | 2024 | 6607 | 0.040 |
Why?
| Paclitaxel | 1 | 2021 | 89 | 0.040 |
Why?
| Morbidity | 1 | 2021 | 145 | 0.040 |
Why?
| Neoplasm Invasiveness | 1 | 2021 | 278 | 0.040 |
Why?
| Cell Movement | 1 | 2021 | 268 | 0.040 |
Why?
| Blood Transfusion | 1 | 2021 | 127 | 0.040 |
Why?
| Pain Measurement | 1 | 2021 | 256 | 0.040 |
Why?
| Software | 1 | 2022 | 280 | 0.040 |
Why?
| Combined Modality Therapy | 1 | 2021 | 639 | 0.040 |
Why?
| Drug Tolerance | 1 | 2019 | 60 | 0.040 |
Why?
| Pandemics | 1 | 2024 | 585 | 0.040 |
Why?
| Survival Rate | 1 | 2021 | 945 | 0.040 |
Why?
| Middle Aged | 2 | 2024 | 13028 | 0.040 |
Why?
| Cohort Studies | 1 | 2021 | 1542 | 0.030 |
Why?
| Rats, Sprague-Dawley | 1 | 2021 | 1563 | 0.030 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 857 | 0.030 |
Why?
| Prognosis | 1 | 2021 | 2099 | 0.030 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 1031 | 0.030 |
Why?
| Analgesics, Opioid | 1 | 2021 | 590 | 0.030 |
Why?
| Prospective Studies | 1 | 2021 | 2481 | 0.030 |
Why?
| Rats | 1 | 2021 | 3220 | 0.030 |
Why?
| Signal Transduction | 1 | 2021 | 1671 | 0.030 |
Why?
| Female | 2 | 2024 | 28171 | 0.030 |
Why?
| United States | 1 | 2024 | 5192 | 0.030 |
Why?
| Aged | 1 | 2024 | 10121 | 0.020 |
Why?
| Child | 1 | 2022 | 7248 | 0.020 |
Why?
|
|
Corrales's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|